Company intelligence / Profile preview

Arrowhead Royalty

Pasadena, California, United Statesrocketreach.co ↗

Ownership: Private
Employees: ~110
Development stage: Other

Overview

Olpasiran demonstrated a ~95% reduction in lipoprotein(a) levels among patients with atherosclerotic cardiovascular disease treated with ≥75 mg every three months. The OCEAN(a)-Outcomes Trial for olpasiran completed enrollment as of May 2024. Plozasiran’s first pivotal Phase III study was set to complete by mid-2024. Arrowhead’s TRiM-enabled candidates have shown rapid and durable knockdown of target genes across multiple indications.

Therapeutic areas: Metabolic DisordersPulmonologyImmunologyRare DiseasesRheumatologyGastroenterologyCardiovascularNeurologyInfectious Diseases
Modalities: Small interfering RNARNA therapyRNA interference (RNAi) therapeuticAntisense oligonucleotide
Industry: Biotech

Partnerships

Amgen (Olpasiran development/commercialization)Johnson & Johnson (Chronic hepatitis B program licensed)Takeda Pharmaceutical (Rare liver disorder program licensed)Horizon Therapeutics (Experimental gout treatment rights)

Beyond the preview

Go deeper on Arrowhead Royalty.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrowhead Royalty.

Explore the full profile